Literature DB >> 26921475

RASSF1A, RECK genotypes and haplotypes in Egyptian population with Hepatocellular carcinoma.

Gehan Abd-Elfatah1, Abdel-Naser Abdel-Atty Gad-Allah2.   

Abstract

BACKGROUND AND OBJECTIVES: The development of HCC is multifactorial, resulting from the interaction of environmental factors (possibly hepatitis viruses) and host factors (genetic factors). So identification of risk factors that contribute to HCC and thus early diagnosis and therapy is necessary. This study aimed to investigate the role of tumor suppressor genes RASSF1A Ala133Ser and RECK rs11788747polymorphisms and their haplotypes in HCC. SUBJECTS AND METHODS: 104 cases of HCC and 100 healthy controls were included in a case-control study. RASSF1A and RECK genotypes, allele and haplotypes were detected by PCR-RFLP.
RESULTS: Risk of HCC was significantly associated with carriers of A1a/Ser, Ser/Ser, Ser allele and A1a/Ser +GA haplotypes (OR=20.57, p<0.001, OR=7.26, p=0.05, OR=10.64, p<0.001, OR=12.52, p=0.005) respectively. More over RECK GG, G allele and haplotype A1a/A1a+GG were protective to HCC (OR=0.11, p<0.001, &amp; OR=0.53, p=0.001 &amp; OR=0.16, p=0.002) respectively. Also, it was found that RASSF1A gene polymorphism significantly associated with bad pathological features but no association with RECK gene polymorphism.
CONCLUSIONS: The RASSF1AAla133Ser polymorphism, RECK gene polymorphism and for the first time haplotype of both genes influence molecular carcinogenesis and clinic pathological features of HCC within the Egyptian population.
Copyright © 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetic susceptibility; Haplotypes; Hepatocellular carcinoma; RASSF1A Ala133Ser & RECK rs11788747 gene polymorphism

Mesh:

Substances:

Year:  2016        PMID: 26921475     DOI: 10.1016/j.imlet.2016.02.013

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  1 in total

1.  Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma.

Authors:  Nermin A Ali; Nadia M Hamdy; Abdullah A Gibriel; Hala O El Mesallamy
Journal:  Arch Virol       Date:  2021-04-01       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.